New Taipei City, Taiwan, Sept. 16, 2025 – Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a Taiwan-based, science-driven biotechnology firm dedicated to creating and commercializing innovative and distinctive plant-derived new drugs, primarily for urinary system diseases, with an initial focus on the U.S., EU, and Asian markets, today announced the successful completion of patient enrollment for its Phase II clinical trial of MCS‑8. This investigational drug candidate, designed for prostate cancer prevention (PCP), has enrolled over 700 high-risk individuals since the trial’s inception.
This randomized, placebo-controlled study is being conducted across 20 hospitals throughout Taiwan, with more than 130 urologists participating.
“We are delighted to have achieved this pivotal milestone in the MCS‑8 development program,” stated Fu-Feng Kuo, Chairwoman and CEO of Jyong Biotech. “We have successfully enrolled more than 700 participants in this clinical trial, and despite the challenging conditions presented by the COVID-19 pandemic, we have reached this objective ahead of our projected timeline. This accomplishment truly underscores the team’s professionalism, patience, dedication, and unwavering commitment.”
MCS‑8 continues to be an investigational new drug candidate and has not received approval for commercial use in any jurisdiction. The Company anticipates analyzing the trial data once the treatment period concludes and will release the results in compliance with applicable disclosure requirements.
About Jyong Biotech Ltd.
Headquartered in Taiwan, Jyong Biotech Ltd. is a science-driven biotechnology company focused on the development and commercialization of innovative, differentiated botanical drugs, primarily for the treatment of urinary system diseases, with initial target markets including the U.S., the EU, and Asia. Since its establishment in 2002, the Company has built comprehensive capabilities spanning all critical aspects of drug development, including early-stage drug discovery, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging robust research and development capabilities and a proprietary platform, the Company is advancing a portfolio of botanical drug candidates, including its lead candidate, BOTRESO®, another clinical-stage botanical drug candidate, and additional preclinical-stage botanical drug candidates. Jyong Biotech aims to develop and provide cutting-edge innovative drugs to address patient health needs and strives to be a respected and valuable business organization.
For more information, please visit: , .
Forward-Looking Statement
This press release contains forward-looking statements. Forward-looking statements encompass statements regarding plans, objectives, goals, strategies, future events or performance, underlying assumptions, and other statements that are not historical facts. When the Company uses terms such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements do not guarantee future performance and involve inherent risks and uncertainties that may cause actual results to differ substantially from the Company’s expectations discussed in these statements. These statements are subject to uncertainties and risks including, but not limited to, those related to market conditions and other factors outlined in the “Risk Factors” section of the registration statement filed with the SEC. For these and other reasons, investors are advised against placing undue reliance on any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are accessible at . The Company disclaims any obligation to publicly update or revise these forward-looking statements to reflect events or circumstances arising after the date hereof.
For more information, please contact:
Investor Relations
WFS Investor Relations Inc.
Janice Wang
Email:
Phone: +1 628 283 9214
